AroCell
0.365 SEK -3.69%2 investors are following this company
AroCell specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. AroCell targets patient groups in different parts of the world. The head office is in Stockholm.
Revenue
43.04M
EBIT %
-138.89 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
AROC
Daily low / high price
0.36 / 0.372
SEK
Market cap
84.08M SEK
Turnover
33.4K SEK
Volume
92K
Latest videos
Financial calendar
Interim report
2024-05-03
General meeting
2024-05-22
Interim report
2024-08-21
Interim report
2024-10-24
Annual report
2025-02-19
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Labbex Förvaltnings AB | 11.6 % | 11.6 % |
Avanza Pension | 8.9 % | 8.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Notice to the 2024 Annual General Meeting of AroCell AB (publ)
New patent approved on the US market
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools